The risk of developing and surviving cancer are shaped by where you live, according to a new report on the situation in Europe.
The report, written by The Swedish Institute for Health Economics (IHE) and commissioned by the European Federation of Pharmaceutical Industries and Association (EFPIA) Oncology Platform, finds deep inequalities in access to prevention and screening, biomarker testing and innovative treatments, and in quality of life for cancer survivors.
The report emphasizes the critical role of efficient use of healthcare budgets in providing high-quality care to address inequalities in patient outcomes. It identifies several common reasons for inequalities, including political prioritisation of cancer care, health expenditure, availability of supporting infrastructure and medical professionals, if clinical guidelines are up to date, geographic distance to health facilities, and health literacy of the public and patients
Key findings:
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze